Recursion uses AI and machine learning to accelerate drug discovery and development for various diseases, including cancers and rare conditions.
Recursion was founded over a decade ago with the goal of using cell images to train artificial intelligence to understand biological space and cellular disruptions driving disease. This AI-driven approach aims to reduce the high failure rate of traditional drug discovery. The company's platform, Recursion OS, integrates data, models, and compute to identify new targets and design optimized molecules. The Recursion OS platform has generated a pipeline of potential first-in-class and best-in-class treatments for conditions with high unmet medical needs. The company claims significant improvements in speed, efficiency, and cost reduction from hit identification to IND-enabling studies compared to traditional pharmaceutical processes. Recursion also engages in strategic partnerships to accelerate discovery and expand its impact, including collaborations with pharmaceutical and technology leaders. Recursion has amassed a proprietary biological and chemical dataset exceeding 50 petabytes, encompassing phenomics, transcriptomics, proteomics, ADME, and de-identified patient data. Their automated wet lab uses robotics and computer vision to conduct millions of cell experiments weekly, feeding results back into the Recursion OS for continuous improvement. They utilize BioHive-2, a supercomputer built with NVIDIA, to process this data and train machine learning models for drug discovery and development.
Integrations: NVIDIA
Platforms: Web
View full Recursion profile on Tools-Radar | Browse Research tools | Alternatives to Recursion
Tools-Radar is a free directory of 10,000+ AI tools — discover, compare, and choose the right AI software for your needs. Visit tools-radar.com